[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357467-105":59,"doc-detail-357467-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","repurposing-registries-completeness-of-real-world-data-for-regulatory-and-hta-purposes-in-three-cancer-focused-registries","Repurposing Registries - Completeness of Real-World Data for Regulatory and HTA Purposes in Three Cancer-Focused Registries","","Repurposing Registries examines how cancer-focused patient and disease registries capture essential data needed for regulatory decision-making and Health Technology Assessment (HTA). The study builds a reference dataset of key data elements using literature and expert input, then evaluates completeness across three European registries: Cancer Centre Upper Austria (CCUA), Dutch Medication Audit (DMA), and RIC IPO Porto. Results show registry aims shape inclusion criteria and create gaps in comorbidities, concomitant therapies, PROMs, resource use, and safety outcomes, underscoring the need for disease-specific core datasets, benchmarking, and further work on interoperability and standardization.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/repurposing-registries-completeness-of-real-world-data-for-regulatory-and-hta-purposes-in-three-cancer-focused-registries/357467/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/repurposing-registries-completeness-of-real-world-data-for-regulatory-and-hta-purposes-in-three-cancer-focused-registries/357467.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s main aim?","Question",{"text":112,"@type":113},"To assess how completely cancer-focused registries collect essential data elements required for regulatory and HTA processes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which registries were evaluated in the study?",{"text":117,"@type":113},"Three European cancer-focused registries were assessed: CCUA, the Dutch Medication Audit (DMA), and the RIC IPO Porto registry.",{"name":119,"@type":110,"acceptedAnswer":120},"Which data element areas were most frequently missing?",{"text":121,"@type":113},"Data related to comorbidities, concomitant therapies, patient-reported outcome measures (PROMs), resource use, and safety outcomes were lacking partly or completely.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},357467,1790190321,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Repurposing Registries: Completeness of Real-World Data for Regulatory and HTA Purposes in Three Cancer-Focused Registries  \nManon C. Wilpshaar1,2, Doranne Hilarius1,3, Luisa Prada4, Ansgar Weltermann5,6 and Christine Leopold7,*   \nDespite developments in supporting the identification and selection of fit-for-purpose registries, a translational gap remains between the original purposes of clinically focused registries and their current and future expected use in policymaking. This study aimed to assess the extent to which cancer-focused registries collect essential data elements for regulatory and Health Technology Assessment (HTA) processes. Using literature and expert input, a reference dataset of essential data elements was developed. Completeness of data elements in this reference dataset was evaluated on the example of three European, cancer-focused registries, varying in type, coverage, and health system: the Cancer Centre Upper Austria (CCUA) registry, the Dutch Medication Audit (DMA), and the Portuguese Oncology Institute of Porto (RIC IPO Porto) registry. The evaluated registries exhibit clear differences in inclusion criteria driven by their specific aims. Data elements related to comorbidities, concomitant therapies, patient-reported outcome measures (PROMs), resource use, and safety outcomes were lacking partly or completely in all evaluated registries, highlighting the importance of developing disease-specific core datasets to which registry holders can benchmark their data collection. This study also highlights that the initial aims and design of registries impact their strengths and weaknesses in supporting regulatory and HTA decision-making. Optimallyrepurposing registry data requires capacity building for registry holders and regulatory/HTA stakeholders focusing on mutual understanding of aims, needs, and limitations. Additional research should address data interoperability, standardization, and data quality across registries.  \nStudy Highlights  \nWHAT IS THE CURRENT KNOWLEDGE ON THIS TOPIC?  \n; Patient or disease registries are increasingly acknowledged by regulatory and Health Technology Assessment (HTA) stakeholders as a Real-World Data (RWD) source to inform their decisions. Specifically in oncology, their relevance is growing as many new therapies enter the market with limited clinical evidence. Despite several frameworks guiding fit-for-purpose assessments, the use of RWD in decision-making is limited. This might be because many registries were originally designed to serve varying clinical purposes rather than decision-making processes.  \nWHAT QUESTION DID THIS STUDY ADDRESS?  \n; Currently, it is not known to what extent patient or disease registries collect data elements that regulatory and HTA decision makers consider essential. Based on guidance documents of regulatory and HTA bodies, a checklist of data elements that are considered essential for decision-making was compiled. On the example of three European registries focused on cancer, we systematically describe registry key  \ncharacteristics, data element completeness, and evolution of completeness.  \nWHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?  \n; Despite their shared focus on cancer, the three registries exhibit clear differences in organizational structure and inand exclusion criteria, which have shaped their data completeness. The largest discrepancies between policymaker-relevant data elements and those currently captured in these registries relate to comorbidities, concurrent therapies, resource use, patient-reported outcomes (PROMs), and safety outcomes. Additionally, the reference dataset that was drafted in this study could be used by other registry holders to benchmark their registries to the needs of policymakers.  \nHOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?  \n; Our findings illustrate how registries can differ even within the same disease areas and underline the importance of defining disease-specific core data","cbCaihQISzE3C04Q","https://ap.wps.com/l/cbCaihQISzE3C04Q","pdf",288377,12,"English","# Study Background\n## Purpose and reference dataset\n## Registries evaluated\n## Key findings on data element gaps\n# Study Highlights\n## Current knowledge\n## Study question\n## Added value to knowledge\n## Clinical pharmacology impact","[{\"question\":\"What was the study’s main aim?\",\"answer\":\"To assess how completely cancer-focused registries collect essential data elements required for regulatory and HTA processes.\"},{\"question\":\"Which registries were evaluated in the study?\",\"answer\":\"Three European cancer-focused registries were assessed: CCUA, the Dutch Medication Audit (DMA), and the RIC IPO Porto registry.\"},{\"question\":\"Which data element areas were most frequently missing?\",\"answer\":\"Data related to comorbidities, concomitant therapies, patient-reported outcome measures (PROMs), resource use, and safety outcomes were lacking partly or completely.\"}]","Repurposing Registries - Completeness of Real-World Data for Regulatory and HTA Purposes in Three Cancer-Focused Registries | PDF",1790130102,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f85c5972c7c91d2dca19143240a4d17e.webp",983,1296,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9042d29c398cc7f5e5380c9439039f4.webp",982,1294,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a24ef91a4c17b31110f92e0abfe62ee.webp",981,1293,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57a8a0e48de461b52b3d6e6736479731.webp",980,1292]